869 1030
Platinum Priority – Review – Prostate Cancer
Editorial by David F. Penson on pp. 886–887 of this issue
Quality of Life Outcomes after Primary Treatment for Clinically
Localised Prostate Cancer: A Systematic Review
Michael Lardas
a ,Matthew Liew
b ,Roderick C. van den Bergh
c ,Maria De Santis
d , e ,Joaquim Bellmunt
f , g ,Thomas Van den Broeck
h , i ,Philip Cornford
j ,Marcus G. Cumberbatch
k ,Nicola Fossati
l , m ,Tobias Gross
n ,Ann M. Henry
o ,Michel Bolla
p ,Erik Briers
q ,Steven Joniau
h ,Thomas B. Lam
r , s ,Malcolm D. Mason
t ,Nicolas Mottet
u ,Henk G. van der Poel
c[2_TD$DIFF]
,Olivier Rouvie`re
v[3_TD$DIFF]
,Ivo G. Schoots
w[4_TD$DIFF]
,Thomas Wiegel
x[5_TD$DIFF]
,Peter-Paul M. Willemse
y[6_TD$DIFF]
,Cathy Yuhong Yuan
z[7_TD$DIFF]
,Liam Bourke
aa[8_TD$DIFF]
, *a
Department of Urology, Leto Hospital, Athens, Greece;
b
Department of Urology, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK;
c
Department of Urology,
[9_TD$DIFF]
Netherlands
[10_TD$DIFF]
Cancer Institute,
[11_TD$DIFF]
Amsterdam, The Netherlands;
d
Clinical Trials Unit, University of Warwick, UK;
e
Department of
Urology, Medical University of Vienna, Austria;
f
Bladder Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA;
g
Harvard Medical School, Boston,
MA, USA;
h
Department of Urology, University Hospitals Leuven, Leuven, Belgium;
i
Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium;
j
Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK;
k
Academic Urology Unit, University of Sheffield, Sheffield, UK;
l
Unit of Urology/Division
of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy;
m
Universita` Vita-Salute San Raffaele, Milan, Italy;
n
Department of Urology, University of Bern,
Inselspital, Bern, Switzerland;
o
Leeds Cancer Centre, St. James’s University Hospital and University of Leeds, Leeds, UK;
p
Department of Radiation Therapy,
CHU Grenoble, Grenoble, France;
q
Hasselt, Belgium;
r
Academic Urology Unit, University of Aberdeen, Aberdeen, UK;
s
Department of Urology, Aberdeen Royal
Infirmary, Aberdeen, UK;
t
Wales Cancer Bank, Cardiff University, School of Medicine, Health Park, Cardiff, UK;
u
Department of Urology, University Hospital,
St. Etienne, France;
v
[1_TD$DIFF]
Hospices Civils de Lyon, Radiology Department, Edouard Herriot Hospital, Lyon, France;
[4_TD$DIFF]
wDepartment of Radiology & Nuclear Medicine,
Erasmus MC University Medical Center, Rotterdam, The Netherlands;
[5_TD$DIFF]
x Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany;
[6_TD$DIFF]
y Department of Urology, University Hospital Groningen, Groningen, The Netherlands;
[7_TD$DIFF]
z Department of Medicine, McMaster University, Hamilton, ON,
Canada;
[8_TD$DIFF]
aa Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 6 9 – 8 8 5ava ilable at
www.sciencedirect.comjournal homepage:
www.eu ropeanurology.comArticle info
Article history:
Accepted June 22, 2017
Associate Editor:
Giacomo Novara
Keywords:
Localised prostate cancer
Quality of life
Patient-reported outcome
measures
Radical prostatectomy
Abstract
Context:
Current evidence-based management for clinically localised prostate cancer
includes active surveillance, surgery, external beam radiotherapy (EBRT) and brachy-
therapy. The impact of these treatment modalities on quality of life (QoL) is uncertain.
Objective:
To systematically review comparative studies investigating disease-specific
QoL outcomes as assessed by validated cancer-specific patient-reported outcome mea-
sures with at least 1 yr of follow-up after primary treatment for clinically localised
prostate cancer.
Evidence acquisition:
MEDLINE, EMBASE, AMED, PsycINFO, and Cochrane Library were
searched to identify relevant studies. Studies were critically appraised for the risk of bias.
A narrative synthesis was undertaken.
Evidence synthesis:
Of 11 486 articles identified, 18 studies were eligible for inclusion,
including three randomised controlled trials (RCTs; follow-up range: 60–72 mo) and
15 nonrandomised comparative studies (follow-up range: 12–180 mo) recruiting a total
of 13 604 patients. Two RCTs recruited small cohorts and only one was judged to have a
* Corresponding author. Collegiate Hall, Collegiate Campus, Sheffield Hallam University, Sheffield,
S10 2BP, UK.
E-mail address:
l.bourke@shu.ac.uk(L. Bourke).
http://dx.doi.org/10.1016/j.eururo.2017.06.0350302-2838/
#
2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.